October is National Healthy Lung Month. Our aglatimagene program targets unmet need in #NSCLC patients with progression despite checkpoint inhibitors. We recently initiated our global phase 3 AURORA trial to advance treatment options. candeltx.com/ #HealthyLungMonth

#ICYMI We’ve appointed Martine Zimmermann, to our board of directors. She brings 30+ years of regulatory affairs and quality experience across multiple stages of drug development. citybiz.co/article/901157/ca… #Leadership

We’re presenting at @sitcancer’s Annual Meeting in November. Two poster presentations on new data from our aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from linoserpaturev in #glioblastoma. ir.candeltx.com/news-release… #SITC26 @baroneExpMed

Our CEO @PaulPeterTak will participate in a fireside chat at the 10th Global Prostate Cancer Summit taking place virtually October 6-8. Learn more: admetech.org/annual-global-s… #GPS2026 #ProstateCancer

New data at @ASTRO_org! Digital pathology analysis demonstrates how aglatimagene activates immune response in localized #ProstateCancer. The quantitative findings support the clinical benefit observed in our phase 3 trial. ir.candeltx.com/news-release… #ASTRO2026

For #ProstateCancerAwarenessMonth, our CEO @PaulPeterTak examines why diagnosis has transformed over two decades, but preventing recurrence in localized prostate cancer treated with curative intent remains an unmet challenge. Read his @UrologyTimes op-ed urologytimes.com/view/after-…

On #WorldCancerResearchDay, we celebrate the research advancing cancer treatment. Candel develops multimodal viral immunotherapies for prostate, lung, pancreatic, and brain cancers. Together with researchers and patients, we aim to build a better future. candeltx.com/

We’re attending @BioCentury Grand Rounds in Amsterdam. Our CEO @PaulPeterTak will moderate a panel, "Rethinking Autoimmunity," on Sept 25. conferences.biocentury.com/g… #Biotech #Innovation

On World Patient Safety Day, we highlight our commitment to safe multimodal viral immunotherapy development. Patient safety guides every step of our clinical work and research. #WorldPatientSafetyDay #PatientSafety

We’re presenting new aglatimagene data at @ASTRO_org 2026. Our Chief Scientific Officer,  @baroneExpMed, is presenting quantitative digital pathology insights from our phase 3 trial in localized #ProstateCancer. ir.candeltx.com/news-release… #ASTRO2026 #Immunotherapy

We’re participating in the H.C. Wainwright Annual Global Investment Conference in New York. Our CEO @PaulPeterTak and CCO Mark Sims will present our corporate and commercial strategy across multiple solid tumor indications. globenewswire.com/news-relea… #HCWCO #HCWConference

We’re headed to NY for Citi’s Biopharma Back to School Conference and Cantor’s Global Healthcare Conference. Our CEO @PaulPeterTak will present a corporate overview and recent highlights. globenewswire.com/news-relea… #CitiBioPharma #CantorHealthcare #ProstateCancer

During #ProstateCancerAwarenessMonth, we recognize patients fighting this disease. Candel is advancing aglatimagene for intermediate- to high-risk localized prostate cancer, with phase 3 data showing meaningful improvements in disease-free survival. candeltx.com/

Tune-in this @urotoday Journal Club discussion highlighting Candel’s phase 3 trial of aglatimagene. After decades of incremental change in localized #ProstateCancer, this data shows improved disease-free survival with a favorable safety profile. urotoday.com/video-lectures/…

Our CEO @paulpetertak spoke with Steve Ruddy on Biotech Leadership Conversations about building for resilience, managing risk, and moving fast when the data comes in. linkedin.com/pulse/biotech-l…

Can we turn a tumor into its own vaccine? Our MOA video explores aglatimagene besadenovec’s biology in localized #ProstateCancer. Combining intraprostate administration, valacyclovir, and radiotherapy designed to induce immunogenic cell death and stimulate anti-tumor immunity.

In this @urotoday interview, Dr. Glen Gejerman discusses Candel’s phase 3 trial of aglatimagene, showing improved disease-free survival in localized #ProstateCancer with a favorable safety profile. urotoday.com/video-lectures/… $CADL

Today we announced Q2 2026 financial results and corporate updates. Highlights included a The Lancet Oncology publication, BLA prep for aglatimagene in localized prostate cancer, and initiation of the phase 3 AURORA trial in #NSCLC. ir.candeltx.com/news-release… $CADL

Our CSO Francesca Barone will be presenting at Canaccord Genuity’s 46th Annual Growth Conference. Get details here: globenewswire.com/news-relea… @baroneExpMed #Biotech #Biopharma $CADL

#ICYMI Proud moment for our team seeing Mark on the @Nasdaq Tower in Times Square. Mark brings 25+ years of oncology commercial expertise as we advance toward BLA submission in Q4 2026 and preparation for potential launch of aglatimagene. ir.candeltx.com/news-release… #Biotech $CADL